Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Hidden and Harmful Pearls of Hidradenitis Treatment
Description
The presentation focuses on the complexities of managing Hidradenitis Suppurativa (HS), a painful skin condition affecting 1-2% of the population, often yielding significant morbidity and a decreased quality of life. The speaker emphasizes the need for comprehensive management strategies, including lifestyle modifications like smoking cessation and weight loss, and the importance of ensuring patients have proper primary care. Medical advancements are discussed, including the use of GLP-1 medications which can aid in reducing inflammation and improving overall health outcomes, particularly for obese patients with HS. Various off-label treatments, like tumor necrosis factor inhibitors and biologics, are highlighted, stressing the need for personalized dosing based on severity. The speaker underscores that successful treatment requires a combination of medical and surgical interventions, such as de-roofing painful sinus tracts, which can significantly improve patient quality of life. An emerging focus on preventative care through laser hair removal and efficient use of prior authorization templates for insurance coverage reveals a commitment to enhance access to optimal treatments. The lecture advocates for early intervention, continuous patient care, and multidisciplinary collaboration in managing the chronic aspects of HS.
View moreConclusions
- Hidradenitis Suppurativa (HS) significantly impacts the quality of life of affected individuals.
- Smoking cessation is crucial as a majority of HS patients smoke, contributing to disease progression.
- Weight loss can lead to substantial improvements in HS symptoms and overall health.
- Glucagon-like peptide-1 receptor agonists (GLP-1s) show potential benefits for HS patients in managing weight and inflammation.
- Early treatment with biologics, particularly anti-TNF agents, is often underutilized in HS management, especially in advanced stages.
- The introduction of newer biologics like secukinumab and bimekizumab marks a significant advancement in HS treatment options.
- Laser hair removal and deroofing techniques are effective in managing HS lesions and improving patient outcomes.
- Individualized treatment plans combining medical and surgical approaches yield the best results for HS patients.
- Alikhan A. J Am Acad Dermatol. 2019 Jul; 81(1): 91-101. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management
- Experimental Dermatology, 2013. 22(3):172-177.
- Figure from Krajewski et al. J Clin Med. 2024, 12(21): 6292.
- Lyons et al. Br J of Derm. 2024;191(4):631-633.
- > J Am Acad Dermatol. 2021 May;84(5):1399-1401. Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: A cross-sectional analysis.
- > JAMA Dermatol. 2022 Feb 1;158(2):184-188. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
- > Lancet 2024; 403:2504-19.
- Shipman et al. Lasers Surg Med. 2024;56(5):425-436.
- > J Am Acad Dermatol. 2020 May;82(5):1094-1101. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa.